These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 9558388)

  • 1. Interleukin-12 inhibits graft-versus-host disease through an Fas-mediated mechanism associated with alterations in donor T-cell activation and expansion.
    Dey BR; Yang YG; Szot GL; Pearson DA; Sykes M
    Blood; 1998 May; 91(9):3315-22. PubMed ID: 9558388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of graft-versus-host disease by interleukin-2 treatment is associated with altered cytokine production by expanded graft-versus-host-reactive CD4+ helper cells.
    Wang MG; Szebeni J; Pearson DA; Szot GL; Sykes M
    Transplantation; 1995 Sep; 60(5):481-90. PubMed ID: 7676498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-12 inhibits murine graft-versus-host disease.
    Sykes M; Szot GL; Nguyen PL; Pearson DA
    Blood; 1995 Sep; 86(6):2429-38. PubMed ID: 7662991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions.
    Blazar BR; Lees CJ; Martin PJ; Noelle RJ; Kwon B; Murphy W; Taylor PA
    J Immunol; 2000 Nov; 165(9):4901-9. PubMed ID: 11046015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-12 prevents severe acute graft-versus-host disease (GVHD) and GVHD-associated immune dysfunction in a fully major histocompatibility complex haplotype-mismatched murine bone marrow transplantation model.
    Yang YG; Dey B; Sergio JJ; Sykes M
    Transplantation; 1997 Nov; 64(9):1343-52. PubMed ID: 9371678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation.
    Min CK; Maeda Y; Lowler K; Liu C; Clouthier S; Lofthus D; Weisiger E; Ferrara JL; Reddy P
    Blood; 2004 Nov; 104(10):3393-9. PubMed ID: 15280194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects.
    Sykes M; Harty MW; Szot GL; Pearson DA
    Blood; 1994 May; 83(9):2560-9. PubMed ID: 7909457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis.
    Reddy P; Teshima T; Kukuruga M; Ordemann R; Liu C; Lowler K; Ferrara JL
    J Exp Med; 2001 Nov; 194(10):1433-40. PubMed ID: 11714750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fas-deficient lpr mice are more susceptible to graft-versus-host disease.
    van Den Brink MR; Moore E; Horndasch KJ; Crawford JM; Hoffman J; Murphy GF; Burakoff SJ
    J Immunol; 2000 Jan; 164(1):469-80. PubMed ID: 10605044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice.
    Yang YG; Sergio JJ; Pearson DA; Szot GL; Shimizu A; Sykes M
    Blood; 1997 Dec; 90(11):4651-60. PubMed ID: 9373279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12.
    Yang YG; Dey BR; Sergio JJ; Pearson DA; Sykes M
    J Clin Invest; 1998 Dec; 102(12):2126-35. PubMed ID: 9854048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD; Becker EE; LaBelle JL; Truitt RL
    J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host-disease.
    Szebeni J; Wang MG; Pearson DA; Szot GL; Sykes M
    Transplantation; 1994 Dec; 58(12):1385-93. PubMed ID: 7809932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
    Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
    J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease.
    Johnson BD; Truitt RL
    Blood; 1995 Jun; 85(11):3302-12. PubMed ID: 7756664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The identification and characteristics of IL-22-producing T cells in acute graft-versus-host disease following allogeneic bone marrow transplantation.
    Zhao K; Zhao D; Huang D; Song X; Chen C; Pan B; Wu Q; Cao J; Yao Y; Zeng L; Xu K
    Immunobiology; 2013 Dec; 218(12):1505-13. PubMed ID: 23816304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects.
    Olson JA; Leveson-Gower DB; Gill S; Baker J; Beilhack A; Negrin RS
    Blood; 2010 May; 115(21):4293-301. PubMed ID: 20233969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The fate of donor T-cell receptor transgenic T cells with known host antigen specificity in a graft-versus-host disease model.
    Dey B; Yang YG; Preffer F; Shimizu A; Swenson K; Dombkowski D; Sykes M
    Transplantation; 1999 Jul; 68(1):141-9. PubMed ID: 10428282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor T cells lacking Fas ligand and perforin retain the capacity to induce severe GvHD in minor histocompatibility antigen mismatched bone-marrow transplantation recipients.
    Marks L; Altman NH; Podack ER; Levy RB
    Transplantation; 2004 Mar; 77(6):804-12. PubMed ID: 15077018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.